clinical trial · NCT06732895
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
AchondroplasiaNavepegritidePlacebo for navepegritide
brief summary
The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.
started
Dec 10, 2024
primary completion
Aug 1, 2027
completion
Sep 1, 2027
last updated
Apr 21, 2026
official title
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-18 Years of Age) With Achondroplasia.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol